ArticleInvestigative ophthalmology & visual science2026
Biomechanical Modification of the Sclera: An Ex Vivo Study on Porcine Eyes.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose: Scleral biomechanics are altered in various ocular pathologies. Modification of sclera biomechanics has been proposed as a potential treatment strategy. This study characterizes the biomechanical effect of collagenase (COL), glyceraldehyde (GAD), microbial transglutaminase (mTG), transglutaminase 1 (TG1), transglutaminase 2 (TG2), and lysyl oxidase (LOX) on ex vivo porcine sclera. Methods: Tissue biomechanics were assessed by uniaxial tensile testing. Tangent modulus (ET) was calculated from the stress-strain curve. The biomechanical response was analyzed based on dose-response curves. Locally applied treatments to the intraocular, extraocular, and combined intra- and extraocular scleral surface were compared with incubated tissue strips. Treatment safety was investigated on human adult retinal pigment epithelium cells (ARPE19) and mouse retinal ganglion cells. Results: GAD 0.1 M and mTG 1 U/mL led to a 10.53-fold (P = 0.0011) and 4.71-fold (P = 0.0210) increase in ET, respectively. COL 0.05 mg/mL decreased tissue stiffness by 2.33-fold (P < 0.0001). Incubation with TG1, TG2, and LOX did not lead to significant changes in tissue ET. The effect of strip incubation was significantly higher for GAD (P < 0.0001) and mTG (P < 0.01) compared with local applications, with no quantitative difference for COL. Viability assays showed a relatively safe application of mTG and COL on retinal ganglion cells and ARPE19, but increased cytotoxicity at higher GAD concentrations. Conclusions: COL, GAD, and mTG induced dose-responsive biomechanical changes in ex vivo scleral biomechanics with acceptable safety. Locally applied treatments showed reduced biomechanical impact compared with strip incubation. Further experiments need to confirm these findings in vivo and determine its role in diseased eyes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.